Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
COR 
Cencora Inc. (COR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/27/2026: COR (4-star) is a STRONG-BUY. BUY since 24 days. Simulated Profits (4.86%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $403.79
1 Year Target Price $403.79
| 10 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 71.32B USD | Price to earnings Ratio 44.07 | 1Y Target Price 403.79 |
Price to earnings Ratio 44.07 | 1Y Target Price 403.79 | ||
Volume (30-day avg) 17 | Beta 0.69 | 52 Weeks Range 246.82 - 376.89 | Updated Date 02/27/2026 |
52 Weeks Range 246.82 - 376.89 | Updated Date 02/27/2026 | ||
Dividends yield (FY) 0.62% | Basic EPS (TTM) 8.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-04 | When Before Market | Estimate 4.04 | Actual 4.08 |
Profitability
Profit Margin 0.5% | Operating Margin (TTM) 1.18% |
Management Effectiveness
Return on Assets (TTM) 3.33% | Return on Equity (TTM) 133.47% |
Valuation
Trailing PE 44.07 | Forward PE 17.64 | Enterprise Value 65833531740 | Price to Sales(TTM) 0.22 |
Enterprise Value 65833531740 | Price to Sales(TTM) 0.22 | ||
Enterprise Value to Revenue 0.21 | Enterprise Value to EBITDA 16.38 | Shares Outstanding 194530682 | Shares Floating 186148355 |
Shares Outstanding 194530682 | Shares Floating 186148355 | ||
Percent Insiders 4.96 | Percent Institutions 96.8 |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora Inc., formerly known as AmerisourceBergen Corporation, was founded in 2001 through the merger of Amerisource Distribution Group and Bergen Brunswig Corporation. It has since grown through strategic acquisitions and organic expansion to become a leading global healthcare company. Its evolution has been marked by a consistent focus on supply chain solutions and services for the pharmaceutical and biotech industries.
Core Business Areas
- Pharmaceutical Sourcing and Distribution: This segment involves the wholesale distribution of a wide range of pharmaceutical products, including branded and generic drugs, to pharmacies, hospitals, and healthcare facilities. It is the largest segment by revenue.
- Specialty Pharmaceutical Distribution: Focuses on the distribution of high-cost, complex specialty drugs used to treat chronic and rare diseases. This segment requires specialized handling and cold chain logistics.
- Pharmaceutical Solutions and Services: This segment offers a suite of services aimed at supporting pharmaceutical manufacturers, including market access, patient support programs, commercialization services, and data analytics.
- Animal Health: Through its subsidiary, Cencora offers a comprehensive range of products and services to veterinarians and animal health businesses, including pharmaceutical distribution and related services.
Leadership and Structure
Cencora Inc. is led by a seasoned executive team, including a Chief Executive Officer, Chief Financial Officer, and heads of various operational and functional divisions. The company is structured into several business units aligned with its core service offerings and geographic regions.
Top Products and Market Share
Key Offerings
- Pharmaceutical Distribution Services: Cencora is a leading distributor of pharmaceuticals in the United States, serving a vast network of healthcare providers. It holds a significant market share in this sector, competing with companies like Cardinal Health and McKesson. Specific revenue figures for individual product categories are not publicly disclosed, but the overall distribution segment is the company's largest.
- Specialty Drug Distribution: Cencora is a key player in the distribution of specialty drugs, which are critical for treating complex conditions. This niche market is growing rapidly, and Cencora's expertise in handling these high-value products positions it well. Competitors include other large distributors and specialized logistics providers.
- Patient Support Programs: The company provides comprehensive patient support services for manufacturers, assisting patients with access, adherence, and financial assistance for their medications. This is a value-added service that strengthens manufacturer relationships.
- Animal Health Products and Services: Cencora provides a broad portfolio of animal health products and services to veterinary professionals. This diversified offering contributes to its overall revenue stream.
Market Dynamics
Industry Overview
The pharmaceutical distribution and healthcare services industry is characterized by consolidation, increasing regulatory scrutiny, and a growing demand for specialty drugs and integrated healthcare solutions. The industry is essential for the delivery of medicines and plays a critical role in the healthcare ecosystem.
Positioning
Cencora is a leading global provider of pharmaceutical distribution and related services. Its competitive advantages include its extensive distribution network, strong relationships with manufacturers and healthcare providers, expertise in specialty pharmaceuticals, and comprehensive suite of value-added services. The company's scale and operational efficiency are also key differentiators.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical distribution and healthcare services is substantial, running into hundreds of billions of dollars globally. Cencora is a significant player within this TAM, particularly in the North American market, and is expanding its global reach. Its positioning is strong due to its established infrastructure and diversified service offerings.
Upturn SWOT Analysis
Strengths
- Extensive and efficient global distribution network.
- Strong relationships with pharmaceutical manufacturers and healthcare providers.
- Leadership in specialty pharmaceutical distribution.
- Diversified revenue streams from various healthcare services.
- Scale and operational efficiencies.
Weaknesses
- Reliance on a few large pharmaceutical manufacturers.
- Potential for pricing pressures from payers and providers.
- Complexity of global supply chain operations.
- Vulnerability to regulatory changes in the healthcare industry.
Opportunities
- Growth in the specialty and biosimilar drug markets.
- Expansion into emerging markets.
- Increased demand for integrated healthcare services and data analytics.
- Strategic acquisitions to expand service offerings and geographic reach.
- Leveraging technology for supply chain optimization.
Threats
- Increased competition from other distributors and new entrants.
- Government regulations and policies impacting drug pricing and distribution.
- Supply chain disruptions (e.g., geopolitical events, pandemics).
- Cybersecurity risks and data breaches.
- Changes in healthcare reimbursement models.
Competitors and Market Share
Key Competitors
- Cardinal Health Inc. (CAH)
- McKesson Corporation (MCK)
Competitive Landscape
Cencora holds a strong position within the pharmaceutical distribution market, directly competing with Cardinal Health and McKesson. Its competitive advantages lie in its specialized services, global reach, and strong manufacturer relationships. However, the market is highly concentrated, and pricing pressures from payers and providers remain a constant challenge. The company must continuously innovate and optimize its operations to maintain its competitive edge.
Major Acquisitions
XXI I.T. Solutions, Inc.
- Year: 2023
- Acquisition Price (USD millions): 150
- Strategic Rationale: To enhance digital capabilities and data analytics services for pharmaceutical partners.
PharMEDium Services LLC
- Year: 2019
- Acquisition Price (USD millions): 400
- Strategic Rationale: To strengthen its capabilities in sterile compounding and outsourced compounding pharmacy services.
Growth Trajectory and Initiatives
Historical Growth: Cencora has achieved consistent growth over the past decade, driven by organic expansion in its core distribution business, strategic acquisitions, and the expansion of its higher-margin solutions and services segments. The company has successfully navigated a dynamic healthcare landscape.
Future Projections: Analyst consensus generally projects continued revenue growth for Cencora, fueled by the expanding pharmaceutical market, increasing demand for specialty drugs, and the ongoing development of its value-added services. Profitability is expected to improve as the company leverages its scale and operational efficiencies.
Recent Initiatives: Recent strategic initiatives include ongoing integration of acquisitions to expand service capabilities and geographic reach, investments in technology to enhance supply chain efficiency and data analytics, and a continued focus on strengthening partnerships with pharmaceutical manufacturers and healthcare providers.
Summary
Cencora Inc. is a robust global healthcare company with a dominant position in pharmaceutical distribution and a growing presence in specialized services. Its extensive network, strong manufacturer relationships, and diversified offerings are significant strengths. However, the company faces ongoing pricing pressures and regulatory challenges inherent in the healthcare industry. Continued strategic investments in technology and potential further acquisitions will be crucial for maintaining its growth trajectory and competitive advantage.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Websites
- SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Wall Street Journal, Bloomberg)
- Industry Analysis Reports
Disclaimers:
This information is for informational purposes only and should not be considered investment advice. Financial data and market share figures are subject to change and are based on publicly available information at the time of generation. Users should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 47000 | Website https://www.cencora.com |
Full time employees 47000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.